BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 28536305)

  • 1. Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.
    Eriksson E; Milenova I; Wenthe J; Ståhle M; Leja-Jarblad J; Ullenhag G; Dimberg A; Moreno R; Alemany R; Loskog A
    Clin Cancer Res; 2017 Oct; 23(19):5846-5857. PubMed ID: 28536305
    [No Abstract]   [Full Text] [Related]  

  • 2. Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy.
    Wenthe J; Naseri S; Labani-Motlagh A; Enblad G; Wikström KI; Eriksson E; Loskog A; Lövgren T
    Cancer Immunol Immunother; 2021 Oct; 70(10):2851-2865. PubMed ID: 33666760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment.
    Eriksson E; Moreno R; Milenova I; Liljenfeldt L; Dieterich LC; Christiansson L; Karlsson H; Ullenhag G; Mangsbo SM; Dimberg A; Alemany R; Loskog A
    Gene Ther; 2017 Feb; 24(2):92-103. PubMed ID: 27906162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1.
    Eriksson E; Milenova I; Wenthe J; Moreno R; Alemany R; Loskog A
    J Immunol; 2019 Feb; 202(3):787-798. PubMed ID: 30617223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human dendritic cells efficiently phagocytose adenoviral oncolysate but require additional stimulation to mature.
    Schierer S; Hesse A; Knippertz I; Kaempgen E; Baur AS; Schuler G; Steinkasserer A; Nettelbeck DM
    Int J Cancer; 2012 Apr; 130(7):1682-94. PubMed ID: 21557217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.
    Wenthe J; Naseri S; Hellström AC; Wiklund HJ; Eriksson E; Loskog A
    Cancer Gene Ther; 2020 Dec; 27(12):948-959. PubMed ID: 32355275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
    Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
    J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
    Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
    Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
    Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
    Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene.
    Fernandes MS; Gomes EM; Butcher LD; Hernandez-Alcoceba R; Chang D; Kansopon J; Newman J; Stone MJ; Tong AW
    Clin Cancer Res; 2009 Aug; 15(15):4847-56. PubMed ID: 19622582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models.
    Wenthe J; Eriksson E; Hellström AC; Moreno R; Ullenhag G; Alemany R; Lövgren T; Loskog A
    J Transl Med; 2023 Jul; 21(1):506. PubMed ID: 37501121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer.
    Liikanen I; Tähtinen S; Guse K; Gutmann T; Savola P; Oksanen M; Kanerva A; Hemminki A
    Mol Cancer Ther; 2016 Sep; 15(9):2259-69. PubMed ID: 27458139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity.
    Schwaiger T; Knittler MR; Grund C; Roemer-Oberdoerfer A; Kapp JF; Lerch MM; Mettenleiter TC; Mayerle J; Blohm U
    Int J Cancer; 2017 Dec; 141(12):2505-2516. PubMed ID: 28857157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.
    Parviainen S; Ahonen M; Diaconu I; Hirvinen M; Karttunen Å; Vähä-Koskela M; Hemminki A; Cerullo V
    Gene Ther; 2014 Feb; 21(2):195-204. PubMed ID: 24305418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.
    Fajardo CA; Guedan S; Rojas LA; Moreno R; Arias-Badia M; de Sostoa J; June CH; Alemany R
    Cancer Res; 2017 Apr; 77(8):2052-2063. PubMed ID: 28143835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes.
    Labani-Motlagh A; Naseri S; Wenthe J; Eriksson E; Loskog A
    Mol Ther Oncolytics; 2021 Mar; 20():508-518. PubMed ID: 33738337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
    Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
    Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.